AKTXAkari Therapeutics

Akari Therapeutics’ CEO Abizer Gaslightwala highlighted the potential of the company’s proprietary platform to treat cancer ahead of ASCO 2026.

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.read more...

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.read more...

Akari Therapeutics shares are surging after preclinical data showed AKTX101 synergized with KRAS inhibition in pancreatic cancer models.read more...

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

Akari said its experimental therapy AKTX-101 showed strong results when paired with an already-approved cancer drug in lab tests on pancreatic cancer cells that carry a common KRAS mutation.

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Akari Therapeutics PLC (NASDAQ:AKTX) sees stock growth fueled by Q1 2026 earnings optimism and a new European patent for its PH1 ADC payload.read more...